Phase 1 trial of TGW101 in advanced solid tumors is enrolling to assess safety and pharmacokinetics and define the maximum ...

Adcentrx Therapeutics, Inc., San Diego, CA.

Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life-threatening diseases, will present the ...

Nijmegen, Netherlands Wednesday, April 23, 2025, 13:00 Hrs [IST] ...

Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a ...

Enfortumab vedotin is now available for patients who received prior platinum-containing chemotherapy and a PD-1/L1 inhibitor ...

10,808,039) covering ADCs that include auristatin compounds coupled to an antibody via a linker molecule. The jury in the US District Court for the Eastern District of Texas agreed with the ...

Blenrep consists of an ADC that features a humanised antibody targeting BCMA, attached to the toxic compound auristatin F through a stable linker. The technology for the drug-linker combination is ...

Nectin-4 is a cell-adhesion molecule expressed in many solid tumors. Enfortumab vedotin (EV, PADCEV ®), an antibody-drug conjugate (ADC) targeting Nectin-4 with a monomethyl auristatin E (MMAE) ...

During a live event, Shannon N. Westin, MD, MPH, and participants discussed their experience treating patients with ...